Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Swiss Exchange  -  11:31 2022-12-09 am EST
85.48 CHF   +0.21%
01:01pErasca Shares Drop 30% After Pricing of $100 Million Underwritten Offering, Novartis Agreement
DJ
09:13aSector Update: Health Care Stocks Steady Premarket Friday
MT
08:58aSector Update: Health Care
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
12/05/2022 12/06/2022 12/07/2022 12/08/2022 12/09/2022 Date
85.8(c) 85.28(c) 85.78(c) 85.3(c) 85.48(c) Last
5 682 880 4 263 382 4 219 643 3 028 243 4 416 531 Volume
+1.97% -0.61% +0.59% -0.56% +0.21% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 51 295 M - -
Net income 2022 8 628 M - -
Net Debt 2022 7 541 M - -
P/E ratio 2022 23,3x
Yield 2022 3,60%
Sales 2023 51 634 M - -
Net income 2023 9 673 M - -
Net Debt 2023 9 495 M - -
P/E ratio 2023 19,9x
Yield 2023 3,73%
Capitalization 197 B 197 B -
EV / Sales 2022 3,99x
EV / Sales 2023 4,00x
Nbr of Employees 108 000
Free-Float 87,1%
More Financials
Company
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (81.3%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal disorders, cancers, central nervous system disorders, hormone imbalances, etc.; - generic drugs (18.7%; Sandoz). Net sales... 
Read more
Sector
Pharmaceuticals
Calendar
12/09 | 08:00amPresentation
More about the company
Ratings of Novartis AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about NOVARTIS AG
01:01pErasca Shares Drop 30% After Pricing of $100 Million Underwritten Offering, Novartis Ag..
DJ
09:13aSector Update: Health Care Stocks Steady Premarket Friday
MT
08:58aSector Update: Health Care
MT
08:17aErasca Signs Worldwide License for Tumor Treatment Naporafenib; Prices Equity Offering
MT
07:31aNOVARTIS AG : Deutsche Bank keeps a Sell rating
MD
12/08NOVARTIS AG : Gets a Neutral rating from Bernstein
MD
12/08NOVARTIS AG : Receives a Buy rating from Goldman Sachs
MD
12/08Novartis Says Phase 3 Trial of Experimental Blood Disease Drug Met Main Endpoint
MT
12/08Novartis Phase 3 Trial for Hemoglobinuria Drug Iptacopan Met Primary Endpoint
DJ
12/08Novartis' Rare Blood Disease Drug Improves Hemoglobin Levels in Late-stage Study
MT
12/08Novartis investigational iptacopan provides clinically meaningful increases in hemoglob..
GL
12/08Novartis investigational iptacopan provides clinically meaningful increases in hemoglob..
DJ
12/07Global markets live: Glencore, Apple, Netflix, Tesla, Amazon...
MS
12/07MorphoSys Out Licenses Pre-Clinical Oncology Program
AQ
12/07NOVARTIS AG : Gets a Sell rating from Deutsche Bank
MD
More news
News in other languages on NOVARTIS AG
12:16pBourse Zurich: le SMI termine dans le vert avant une semaine cruciale
12:16pAktien Schweiz Schluss: Technische Gegenbewegung nach fünf Verlus..
11:44aBorsa svizzera: chiude in rialzo, SMI +0,58%
11:40aAktien Schweiz schließen freundlich - Credit Suisse gesucht
09:13aMise à jour sectorielle : Les actions du secteur de la santé res..
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Stock Trading Strategies
NOVARTIS AG - 2021
Comeback of a rising trend?
BUY
More Stock Trading Analysis
ETFs positioned on NOVARTIS AGETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
UBS ETF (CH) - SMI A-dis - CHF17.78%-2.17%Switzerland
IShares SMI (CH) - CHF17.24%-2.23%Switzerland
IShares Swiss Dividend (CH) - CHF14.95%-2.07%Switzerland
Xtrackers Switzerland - 1D - CHF14.41%-2.71%Switzerland
Xtrackers Switzerland - 1C - CHF14.18%-2.24%Switzerland
More ETFs positioned on NOVARTIS AG
Analysis
Novartis earnings slip 4% on strong dollar, Gilenya competition
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 91,67 $
Average target price 92,79 $
Spread / Average Target 1,22%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans Jörg Reinhardt Non-Executive Chairman
Shreeram Aradhye Chief Medical Officer
Steffen Lang President-Operations
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG6.25%196 152
JOHNSON & JOHNSON3.57%463 286
ELI LILLY AND COMPANY34.66%353 267
ABBVIE INC.22.59%293 450
PFIZER, INC.-14.92%290 657
NOVO NORDISK A/S22.08%287 434